Phase 3 Readout
QNRX: Phase 3 Topline: A Single Center, Open Label, Expanded Access Study of QRX003 Lotion in Subjects With Netherton Syndr
July 30, 2026 · qrx003. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- July 30, 2026
- Company
- Quoin Pharmaceuticals, Ltd. (QNRX)
- Drug
- qrx003
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Single Center, Open Label, Expanded Access Study of QRX003 Lotion in Subjects With Netherton Syndr
- Drug
- qrx003
- Indication
- Netherton Syndrome